Erasca Inc. Unveils Presentation on Their Mission to Erase Cancer and Innovative RAS/MAPK Pathway Strategies

Reuters

2025/08/13

Erasca Inc. Unveils Presentation on Their Mission to Erase Cancer and Innovative RAS/MAPK Pathway Strategies

Erasca Inc. has presented its latest corporate update, highlighting its commitment to advancing oncology treatments with a focus on the RAS/MAPK pathway. The company, founded by Jonathan Lim, MD, and Kevan Shokat, PhD, is leveraging its experienced leadership team and a world-class scientific advisory board to target RAS-related cancer pathways. Erasca's pipeline includes promising candidates like ERAS-0015 and ERAS-4001 aimed at tackling RASm and KRASm solid tumors, respectively. Financially, Erasca is in a strong position with $387 million in cash, cash equivalents, and marketable securities, providing a cash runway into the second half of 2028. The company was recognized as one of Fierce Biotech's 2021 "Fierce 15" most promising biotechnology companies. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief on August 12, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2559262194"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559262194\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559262194?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-13 04:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559262194","market":"nz","top_or_hot":-1,"title":"Erasca Inc. Unveils Presentation on Their Mission to Erase Cancer and Innovative RAS/MAPK Pathway Strategies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Erasca Inc. Unveils Presentation on Their Mission to Erase Cancer and Innovative RAS/MAPK Pathway Strategies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Erasca Inc. has presented its latest corporate update, highlighting its commitment to advancing oncology treatments with a focus on the RAS/MAPK pathway. The company, founded by Jonathan Lim, MD, and Kevan Shokat, PhD, is leveraging its experienced leadership team and a world-class scientific advisory board to target RAS-related cancer pathways. Erasca's pipeline includes promising candidates like ERAS-0015 and ERAS-4001 aimed at tackling RASm and KRASm solid tumors, respectively. Financially, Erasca is in a strong position with $387 million in cash, cash equivalents, and marketable securities, providing a cash runway into the second half of 2028. The company was recognized as one of Fierce Biotech's 2021 \"Fierce 15\" most promising biotechnology companies. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Erasca Inc. Unveils Presentation on Their Mission to Erase Cancer and Innovative RAS/MAPK Pathway Strategies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nErasca Inc. Unveils Presentation on Their Mission to Erase Cancer and Innovative RAS/MAPK Pathway Strategies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-13 04:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Erasca Inc. Unveils Presentation on Their Mission to Erase Cancer and Innovative RAS/MAPK Pathway Strategies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Erasca Inc. has presented its latest corporate update, highlighting its commitment to advancing oncology treatments with a focus on the RAS/MAPK pathway. The company, founded by Jonathan Lim, MD, and Kevan Shokat, PhD, is leveraging its experienced leadership team and a world-class scientific advisory board to target RAS-related cancer pathways. Erasca's pipeline includes promising candidates like ERAS-0015 and ERAS-4001 aimed at tackling RASm and KRASm solid tumors, respectively. Financially, Erasca is in a strong position with $387 million in cash, cash equivalents, and marketable securities, providing a cash runway into the second half of 2028. The company was recognized as one of Fierce Biotech's 2021 \"Fierce 15\" most promising biotechnology companies. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ERAS","symbol_name":"Erasca, INC.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDL5GBkmL:1","article_id":"2559262194","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559262194","pubTimestamp":1755029883,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Erasca Inc. has presented its latest corporate update, highlighting its commitment to advancing oncology treatments with a focus on the RAS/MAPK pathway. The company, founded by Jonathan Lim, MD, and Kevan Shokat, PhD, is leveraging its experienced leadership team and a world-class scientific advisory board to target RAS-related cancer pathways. Erasca's pipeline includes promising candidates like ERAS-0015 and ERAS-4001 aimed at tackling RASm and KRASm solid tumors, respectively. Financially, Erasca is in a strong position with $387 million in cash, cash equivalents, and marketable securities, providing a cash runway into the second half of 2028. The company was recognized as one of Fierce Biotech's 2021 \"Fierce 15\" most promising biotechnology companies. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ERAS":"Erasca, INC.","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"Erasca Inc.公布了他们消除癌症的使命和创新的RAS/MAPK途径策略","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ERAS":0.9},"content_text":"Erasca Inc. Unveils Presentation on Their Mission to Erase Cancer and Innovative RAS/MAPK Pathway Strategies\n    \n\n        Erasca Inc. has presented its latest corporate update, highlighting its commitment to advancing oncology treatments with a focus on the RAS/MAPK pathway. The company, founded by Jonathan Lim, MD, and Kevan Shokat, PhD, is leveraging its experienced leadership team and a world-class scientific advisory board to target RAS-related cancer pathways. Erasca's pipeline includes promising candidates like ERAS-0015 and ERAS-4001 aimed at tackling RASm and KRASm solid tumors, respectively. Financially, Erasca is in a strong position with $387 million in cash, cash equivalents, and marketable securities, providing a cash runway into the second half of 2028. The company was recognized as one of Fierce Biotech's 2021 \"Fierce 15\" most promising biotechnology companies. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief on August 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}